source
- Rezera delays $200M IPO amid weak market conditionsRezera, a biotech developing drugs for cardiovascular and inflammatory diseases, announced that it will not proceed with its planned initial public offering that had been scheduled for Friday. The…
- Abiomed issues recall of Automated Impella Controllers due to safety riskAbiomed has announced a recall of certain Automated Impella Controllers (AIC) after a review of service records. The FDA classified the recall as the most serious type, warning that continued use…